JamesGSM, actually :"waiting for the company', Dr. Wolchock words in relation to a clinical trial ready in his lab.
He didn't say the name of the company, nor the title of the clinical trial. However, he brought it up in response to a question, after an refresh intro to a previous conversation related to anti-PtdSer being the apparent solution for IO combo foot-print increase, and after a CAR-T reference to his own work.
But one thing is CLEAR: Dr. Wolchok is waiting because "WHOEVER" the company is, they told him NOT to move forward but WAIT. That alone points that something is going on because if the company was the NEW PtdSer IP/Pipeline owner then they could give the green light. But if there isn't one officially yet (e.g. in negotiation) then PPHM/CDMO would be the company if we are talking about a CAR-T+anti-PtdSer in humans.
Such clinical trial CANNOT have been prepared without at least PPHM/CDMO and the CAR-T party (GILD/Kite, Celgene/Juno, Roche,...) BOTH being involved and aware because they deliver the drugs.
And AGAIN the patents are NOT end-of life. We have seen that delaying PPHM from 2012 till 2017 (incl). with the dose switching was what the market needed to do some catch-up and put some barriers in place in the form of higher SOC's and 3rd party treatments.
So 4-7 years Bavi (extension) is more then sufficient to advance a research program in the state of PPHM's pipelines where all the initial trails have been done and accepted by the FDA. No more questions about Bavi toxicity for instance and whether it is tolerated or has side effects of its own.
With biomarkers the needed time can be seriously reduced. And BETABODIES has even better and more recent IP.
Liquid Biopsy has the most recent IP and was a few months ago near production grade. It score 99+% accuracy, had only 2 false predictions that were explained and the test has been tuned accordingly. By memory one woman's Ovarian cancer was masked by breast cancer.
Where is that technology. It has a LARGER market potential then the CAR-T IMO. Furthermore Avid has an ALL-Targets platform that they were going to add to there full CDMO service. Where is it? Lias said the possibilities were endless YET not a word about it on his slides and nothing in his spoken part that referred to it AT ALL.
I am not in a US context but some of you should think about what more then just letters can be done over there to :
- Force PPHM/CDMO to involve a 3rd party to VALUATE the R&D program
- Force such party to AT LEAST contact CEO/CTO etc of BP's
- Force them to LIST the assets so that nothing disappears between the lines.
And it needs to be done pro-actively because otherwise they will probably say stuf as: We didn't know, we tought, we assumed, etc.
We have a CDMO BoD that is selling an R&D portfolio with the patents for binding to one of the MOST TALKED ABOUT molecules in Cancer and other treatment: Phosphatidylserine.
AIMO.
News 
Market Data 
Discover 
